Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 (Toripalimab) in Advanced Gastric, Esophageal, Nasopharyngeal, and Head and Neck Cancers
NCT02915432Phase 2Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in gastric adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), nasopharyngeal carcinoma (NPC) and 1 more (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Objective Response Rate up to 1.5 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)nasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02915432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915432.